Peer Review History

Original SubmissionSeptember 1, 2025
Decision Letter - Madhuradhar Chegondi, Editor

Dear Dr. Rabelo-Silva,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 17 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Madhuradhar Chegondi, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

4. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table.

5. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files

6. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission.

7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??>

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

Reviewer #1: Interesting protocol

Some issues should be addressed

1) background in abstract shoudld be shortened

2)methods: it is not clear how randomization will be performed

3)sample calculation is not clear to me>authors should state if they start from some infections rates and go back to others. Moreover it should be performed on primary end point

4) do authors think that subgroup analysis should be performed

Reviewer #2: In this ambitious multicentric trial, the authors wish to investigate if tunneled PICC lines in adult patients provide benefit compared to standard PICC insertion techniques. In this trial, the authors wish to enroll 840 patients in three centers in Brazil and use stratified randomization. The primary outcome variable is the isolated or combined adverse events from PICC lines (infection, thrombosis, obstruction, or dislodgement).

Overall, the study design is pretty straightforward. In the supplemental protocol, the authors mentioned that the study team members inserting the tunnel for clients would be specifically trained. It is fairly ambitious with the amount of funding available to them. But if baseline insertions are part of standard patient management, then it should be feasible.

The authors’ sample size is based on an estimate of a 50% reduction in composite outcomes. This appears very, very optimistic. The authors have not provided any information on how they estimated a 50% reduction. This is important because an inadequately powered study (because of overestimation of potential benefit) with standard frequentist analysis is very likely to lead to a null effect.

The authors also mentioned that the research team would be blinded for tunneled vs. non-tunneled catheters. This is really not very feasible, as it is easy to identify tunneled vs. non-tunneled catheters. While blinding at the time of analysis can be ensured, data collection would have to be open-label, which is okay, as blinding is not realistic in this type of study.

The authors have also not mentioned any data collection on the success rate of inserting tunneled catheters and complications/costs associated with tunneled catheters compared to standard insertions. It seems like the authors wish to do an intention-to-treat analysis, which is okay. However, they should also do a per-protocol analysis as a sensitivity analysis.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes: Fabrizio D'Ascenzo

Reviewer #2: Yes: Sandeep Tripathi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

Revision 1

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. OK

2. Please update your submission to use the PLOS LaTeX template. OK

3. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure. Referred

4. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table. Referred

5. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files. OK

6. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission. Removed

Reviewer #1:

background in abstract should be shortened

The background in abstract was shortened – Page 2

methods: it is not clear how randomization will be performed

The randomization was better described in methods – Page 7

sample calculation is not clear to me>authors should state if they start from some infection rates and go back to others. Moreover it should be performed on primary end point

Sample calculation was based on previous article, according to what is described in Sample size – Page 6

HONG, Jiana; MAO, Xiaodan. Complications of tunneled and non-tunneled peripherally inserted central catheter placement in chemotherapy-treated cancer patients: a meta-analysis. Frontiers in Surgery, v. 11, p. 1469847, 2024.

do authors think that subgroup analysis should be performed

We understand that a subgroup analysis could be performed, particularly with onco-hematologic patients. However, subgroup analysis will be conducted a posteriori.

Reviewer #2:

The authors’ sample size is based on an estimate of a 50% reduction in composite outcomes. This appears very, very optimistic. The authors have not provided any information on how they estimated a 50% reduction. This is important because an inadequately powered study (because of overestimation of potential benefit) with standard frequentist analysis is very likely to lead to a null effect.

Sample calculation was based on previous article, according to what is described in Sample size – Page 6;

HONG, Jiana; MAO, Xiaodan. Complications of tunneled and non-tunneled peripherally inserted central catheter placement in chemotherapy-treated cancer patients: a meta-analysis. Frontiers in Surgery, v. 11, p. 1469847, 2024.

The authors also mentioned that the research team would be blinded for tunneled vs. non-tunneled catheters. This is really not very feasible, as it is easy to identify tunneled vs. non-tunneled catheters. While blinding at the time of analysis can be ensured, data collection would have to be open-label, which is okay, as blinding is not realistic in this type of study.

Thank you for your observation. However, the professionals responsible for assessing the outcomes will not be directly involved with the patients. The presence or absence of each outcome will be determined based on medical records.

The authors have also not mentioned any data collection on the success rate of inserting tunneled catheters and complications/costs associated with tunneled catheters compared to standard insertions. It seems like the authors wish to do an intention-to-treat analysis, which is okay. However, they should also do a per-protocol analysis as a sensitivity analysis.

Thank you for your observation. All analyses will be performed following the intention-totreat principle. This is included in the analyses section.

Attachments
Attachment
Submitted filename: Reply letter.docx.pdf
Decision Letter - Madhuradhar Chegondi, Editor

TUNNELED PERIPHERALLY INSERTED CENTRAL CATHETER VERSUS NON-TUNNELED AND ITS EFFECTS IN CLINICAL OUTCOMES: A MULTICENTER RANDOMIZED CLINICAL TRIAL PROTOCOL

PONE-D-25-38258R1

Dear Professor Eneida Rejane Rabelo-Silva,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Madhuradhar Chegondi, MD

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

Reviewer #1: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??>

Reviewer #1: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??>

Reviewer #1: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete??>

The PLOS Data policy

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

Reviewer #1: all comments have been addressed and authors should be complimented for this good revision again, although synthetic in answers

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes: Fabrizio D'Ascenzo

**********

Formally Accepted
Acceptance Letter - Madhuradhar Chegondi, Editor

PONE-D-25-38258R1

PLOS One

Dear Dr. Rabelo-Silva,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Madhuradhar Chegondi

Academic Editor

PLOS One

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .